---
title: "HPV prevalence and genotype distribution in women from northern Lao PDR (2018–2019)"
id: "plos-one-15-prevalence-and-genotype-distribution-of-human-papillomavirus-in-women-from"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-15-prevalence-and-genotype-distribution-of-human-papillomavirus-in-women-from"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0363215"
published_at: "2026-11-20T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# HPV prevalence and genotype distribution in women from northern Lao PDR (2018–2019)
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-15-prevalence-and-genotype-distribution-of-human-papillomavirus-in-women-from
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0363215)
- **Published At:** 2026-11-20T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Cross-sectional survey of 1,302 asymptomatic women (mean age 37.4 years) in four northern Lao provinces collected cervical cytology and swabs for PCR and Anyplex II HR-HPV testing. - Cytology was evaluable in 1,268 samples; 114 (9.0%) had abnormal cytology and three (0.2%) had cancer. - Anyplex II detected HR-HPV in 256 of 1,184 valid samples (21.6%); all 14 targeted HR types were found. - **HPV 52**, **HPV 58** and **HPV 16** were the three most common high-risk genotypes detected by Anyplex (20.4%, 12.8%, 11.7% of detections respectively). - In-house GP5+/GP6+ PCR produced 277 positives (21.3%); discordant results occurred between assays including 41 PCR+/Anyplex– and 37 Anyplex+/PCR– samples. - Multiple genotype infections were common: 100 Anyplex-positive samples contained more than one genotype; 37.3% of HR-HPV positives in women with normal cytology had ≥2 types. - HR types found in women with abnormal cytology included 16, 18, 33, 39, 51, 52, 58 and 68; HPV 52 was the single most frequent in that subgroup (22.2% of HR detections among abnormal cytology). - Multivariable analysis indicated age ≥40 years and residence in Luangprabang province were associated with higher odds of abnormal cytology; single/divorced/widowed status was associated with higher odds of HPV detection compared with married women. - Authors recommended consideration of the **nonavalent vaccine** given the genotype mix and periodic screening for women too old to have benefited from the national quadrivalent program. - The study noted limitations: provincial selection was based on collaborator availability, some test results were invalid/borderline and cytology quality exclusions occurred; these factors affect generalisability and interpretation.
## Clinical Analysis & Structured Key Points
Prevalence and genotype distribution of human papillomavirus in women from northern provinces of Lao People’s Democratic Republic, 2018–2019 | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Peer Review Reader Comments Figures Figures Abstract Background Cervical cancer is a frequent cause of morbidity and mortality in women worldwide and strongly linked to the presence of high-risk (HR) human papillomavirus (HPV) genotypes. The present study aimed to determine HPV prevalence and genotypes and their relationship with cytology results in Lao women. Methods Between October 2018 and February 2019, a total of 1302 asymptomatic women (mean age 37.4 years, range 18–76) from Xiengkhouang, Luangprabang, Oudomxay and Huaphan provinces were invited to answer a questionnaire, and cervical cells were collected for cytology and a swab for PCR and Anyplex TM II HPV-HR detection. Results Overall, 114 of 1268 women with evaluable samples (9.0%) had abnormal cytology and three (0.2%) had cervical cancer. Anyplex TM II HPV-HR kit detected 256 positives among 1184 participants (21.6%), with types 52, 58 and 16 being the most prevalent HR genotypes (20.4%, 12.8% and 11.7%, respectively). Multivariable analysis showed that participants aged ≥ 40 years (OR: 1.6; 95% CI: 1.1–2.4, p = 0.015) and those living in Luangprabang province (OR: 1.9; 95% CI: 1.1–3.2, p = 0.02) had a higher likelihood of abnormal cytology compared to younger women and those residing in Huaphan. Single/divorced/widow women had a higher probability of HPV detection compared to married women (OR: 2.3; 95% CI: 1.5–3.7, p < 0.001). Conclusions HPV 52, 58 and 16 were the most prevalent high-risk genotypes, clearly advocating for the introduction of the nonavalent vaccine. Periodic screening of women too old to benefit from the recently introduced vaccine should be considered. Citation: Khounvisith V, Samountry B, van Beek J, Sausy A, Brunnhoefer R, Vongphachanh B, et al. (2026) Prevalence and genotype distribution of human papillomavirus in women from northern provinces of Lao People’s Democratic Republic, 2018–2019. PLoS One 21(11): e0363215. https://doi.org/10.1371/journal.pone.0363215 Editor: Cecilia Acuti Martellucci, University of Bologna: Universita di Bologna, ITALY Received: July 8, 2026; Accepted: November 5, 2026; Published: November 20, 2026 Copyright: © 2026 Khounvisith et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: The minimal anonymized dataset necessary of this study is provided as Supporting Information . Data potentially identify individual participants are not publicly available because of ethical and confidentiality restrictions imposed by the National Ethics Committee for Health Research (NECHR), Lao PDR. Funding: Ministry of Foreign and European Affairs, Defence, Development Cooperation and Foreign Trade (“PaReCIDS II). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: The authors have declared that no competing interests exist. Abbreviations: ASCUS, Atypical squamous of undetermined significance; CIN, Cervical Intraepithelial Neoplasia; HPV, Human papillomavirus; HR-HPV, High Risk-Human papillomavirus; HSIL, High grade squamous intraepithelial lesion; Lao PDR, Lao People’s Democratic Republic; LBC, Liquid Based Cytology; LR-HPV, Low Risk- Human papillomavirus; LSIL, Low-grade squamous intraepithelial lesion; NECHR, National Ethics Committee for Health Research; OR, Odds ratio; PCR, Polymerase Chain Reaction; SCC, Squamous cell carcinoma; UHS, University of Health Science; VIA, Visual Inspection with Acetic acid Introduction Human papillomavirus (HPV) belongs to the Papillomaviridae family and at least 150 genotypes are known. More than 40 genotypes can be transmitted by sexual contact via the skin and mucous membranes. The HPV genotypes can be divided into low-risk HPV (LR-HPV) (types 6, 11, 40, 42, 43, 44, 53, 54, 61, 72, 73, 81) and high-risk HPV (HR-HPV) (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) based on the associated risk of cervical cancer [ 1 , 2 ]. Cervical cancer is the fourth most common cancer in women globally. In 2020, it was estimated that every year 600,000 new cervical cancer cases are detected and more than half of them die as a result of the disease [ 3 ]. About 85% of cervical cancer deaths are thought to occur in developing countries [ 4 ]. Worldwide, HPV 16 and 18 are linked with 70–75% of cervical cancer cases and 50% of cervical intraepithelial neoplasia grade 3 (CIN3), a precancerous condition [ 5 ]. Studies in healthy young women from Japan and China have reported that the most prevalent HR-HPV types are 16 and 52 [ 6 , 7 ]. Risk factors for infection with HR-HPV include, e.g., early age of first sexual contact, high lifetime number of sexual partners and many years of oral contraceptive use [ 8 – 10 ]. Cervical cancer screening consists of visual inspection with acetic acid (VIA) or cervical cytology (e.g., Pap test) and molecular screening is used to detect HR-HPV subtypes. VIA is a primary screening in low- and middle-income countries since it is easy to perform and not expensive [ 11 ]. However, sensitivity and specificity are suboptimal [ 12 ]. The Pap test is used to detect precancerous lesions and consists of collecting cervical cells, fixing them on a slide and examining them under a microscope. Although in principle easy to perform, the quantity and/or quality of the collected cells are sometimes inappropriate for a proper evaluation of the specimen. In addition, the sensitivity to detect precancerous lesions has been reported to be only around 55%, while a high specificity of 96.8% was found [ 13 ]. Liquid-based cytology (LBC) is an alternative method using a brush or spatula to collect material, which is then transferred into a vial containing a fixative liquid. Some studies showed that the low-grade cytologically abnormal stages are more often detected with LBC [ 14 ], which was reported to have a sensitivity and specificity of 94.6% and 94.1% respectively [ 13 ]. LBC is thought to reduce false negative results due to low-quality smears and is fast, but expensive [ 15 ]. Cytology and histology results are observer-dependent and especially in low-and-middle-income countries, including Lao People’s Democratic Republic (Lao PDR), trained pathologists are rare, which limits diagnostic capacity and may delay result interpretation. The Lao population comprises about 2.26 million women aged 15 years and older, who are at risk of developing cervical cancer [ 16 ]. Since 2020, Lao PDR has implemented a national HPV vaccination program, which is largely school-based and targets adolescent girls aged 10–14 years. Currently the quadrivalent vaccine against HPV types 6, 11, 16 and 18, the most common causes of cervical cancer, is used [ 17 ]. In 2021, an estimated 300 cases of cervical cancer occurred in Lao PDR, resulting in the classification of cervical cancer as the fourth most frequent cancer in Lao women and the third most common in women between 15 and 44 years [ 16 ]. A study conducted in 2008 showed that 58% of Lao women had heard of cervical cancer and 38% considered themselves to be at risk, but only 5% had done a Pap test [ 18 ]. Another study from 2009 conducted in 1922 asymptomatic women from 3 provinces (Vientiane Capital, Luangprabang and Champasack province) found an HR-HPV prevalence of 11% in women visiting gynaecology departments with the most common types being HPV 33, 52 and 58 (3%), HPV 16 (2%) and HPV 18/45 (1%) [ 8 ]. However, that study did not determine the associations between HPV type and cervical cytology. In 2017, a study among asymptomatic healthy females in Vientiane capital found that 9.3% (132/1422) had abnormal cytology and 47.7% of these (63/132) were HR-HPV positive. The most common types were HPV 16 (20.5%) and HPV 58 (9.1%) [ 19 ]. This study aimed to determine the HPV prevalence, genotype distribution, and risk factors in asymptomatic women in 4 provinces in Lao PDR in order to inform future screening and vaccination strategies and to monitor control efforts. In addition, and due to so far limited information, the relationship between cytology and HPV prevalence and types was investigated. Methodology Study population This cross-sectional study conducted between October 2018 and February 2019 targeted asymptomatic Lao women from Xiengkhouang, Luangprabang, Oudomxay and Huaphan provinces. The provinces were selected by the University of Health Science (UHS) according to the availability of onsite collaborators to participate in the study. Participants were recruited if they were Lao women of at least 18 years of age and had signed the consent form. Exclusion criteria were pregnancy, recent cancer, hysterectomy, or any serious medical morbidities. Sample and data collection Health care staff at the provincial hospitals and village chiefs in the selected study areas were informed about the study before sample collection and health care workers trained. Interviews and sample collection were conducted in dedicated rooms at the provincial hospitals. The study objectives and procedures were explained to all participants. Written informed consent was obtained from literate participants, while the consent form was read aloud to illiterate participants, who provided consent by fingerprint. A questionnaire capturing socio-demographic characteristics, lifestyle factors related to HPV infection, and other potential risk factors such as age of first sexual contact, number of sex partners, smoking etc. was administered. After the interview, cervical cells were collected by the gynaecologist or responsible doctor, fixed and stained following standard Pap test methodology [ 20 ]. An additional swab was taken by using cervical sampler (a broom-like device), according to the instructions provided by the manufacturer [ 21 ]. Samples were stored for maximum 7 days at 4°C before their transport to Institut Pasteur du Laos (liquid sample for PCR) and UHS (fixed slides for cytology analysis). Cytological interpretation was based on the Bethesda System [ 22 ]. All Pap test results were sent back to the designated doctor at the provincial hospital, who communicated them to the participants. DNA extraction HPV DNA was extracted from cervical cells by using QIAamp DNA kits according to the manufacturer’s instructions [ 23 ]. DNA was eluted in 100 µl of AF buffer and then stored at −20°C. An extraction control (hepatitis B virus DNA positive serum) was used to assess extraction quality of each run. Two different HPV detection methods were used for sample screening, namely a more affordable and broad-range HPV in-house assay and a commercial assay for HR detection and genotype determination requiring a specific platform to compare performance and suitability for routine screening of asymptomatic women. Specifically, DNA amplification was done by in-house PCR using GP5 + /GP6 + primers [ 24 ], generating an amplicon of 150 bp. For each PCR, positive controls (extracted DNA from HPV16 and HPV18 virus culture) and a negative control (water) were included. PCR products were analysed by gel electrophoresis on a 1% agarose gel. Samples were considered HPV-positive when the PCR product of the expected size was visible on the gel. In addition, all samples were tested with the Anyplex™ II HPV HR Detection kit (Seegene) according to the manufacturer’s manual [ 25 ] to identify HPV-HR genotypes. Data analysis Data were analysed by STATA version 14. Descriptive analysis included independent variables such as age, ethnicity, occupation, education, marital status, income, age at first sexual contact, number of sexual partners, previous cervical screening, vaginal infection, smoking and use of oral contraceptives. Chi-square or Fisher’s exact tests were done for bivariate analysis using independent variables and HPV genotype in relation to cytology, Anyplex TM II HPV HR and PCR results. Variables with a p-value lower than 0.2 were included in the model. Variables considered potential confounders, regardless of p-value, such as province, age, ethnicity, occupation, education, marital status, number of sexual partners and vaginal infection were also incorporated into the regression analysis. All associations were evaluated for significance at p < 0.05. Ethical considerations The study proposal was approved by the Institut Pasteur du Laos ethics committee and the Lao National Ethics Committee for Health Research (088/NECHR). All women were informed about the study objectives, procedures, potential risks and benefits prior to sample collection. Written or fingerprint consent (for participants unable to provide a signature) was obtained from all participants before conducting the interviews. Participation was voluntary and participants were informed of their right to withdraw from the study at any time without consequence. Confidentiality and anonymity of participant information were strictly maintained throughout the study. The study was conducted in accordance with the Declaration of Helsinki. Results Participant characteristics A total of 1302 women were included in this study with a mean age of 37.4 years (standard deviation (SD) 9.1 years, range 18–76 years). Most women (n = 1127, 86.6%) belonged to the Lao-Loum ethnicity. About half (n = 655, 50.3%) were government staff and 23% (n = 300) were shop owners. Overall, 410 (31.5%) women completed secondary high school and 264 (20.3%) had a bachelor degree. The vast majority (n = 1197, 91.9%) were married. More than half of the women (n = 713, 54.8%) had their first sexual contact at the age of 20–25 years and 230 (17.7%) indicated to have had more than one sexual partner. Only 404 (31%) participants reported that they had a previous cervical screening (n = 393, 30.2% had a Pap test and n = 11, 0.8% a VIA). About one quarter of the women (n = 328, 25.2%) reported that they have had vaginal infection or sexually transmitted diseases (STD) and candidiasis was most often named (n = 247, 75.8%). A total of 1049 (80.6%) women had used contraceptives, with the pill being most often used (n = 375, 35.8%) ( Table 1 ). Download: PNG larger image TIFF original image Table 1. Participant characteristics. https://doi.org/10.1371/journal.pone.0363215.t001 Cytological examination Pap test results based on the Bethesda system showed that 1151 of the 1268 women with evaluable swabs (90.8%; 34 specimens of low quality had to be excluded) had normal cytology. A total of 114 women (9.0%) had an abnormal cytology and three (0.2%) had cervical cancer (squamous cell carcinoma and adenocarcinoma) ( Table 2 ). Download: PNG larger image TIFF original image Table 2. Cytology results of the 1268 women with evaluable Pap tests. https://doi.org/10.1371/journal.pone.0363215.t002 Anyplex TM II HPV HR detection Of the 1302 samples tested, 118 yielded invalid (n = 24) or borderline (n = 94) results and had to be excluded. Overall, 256 of the remaining 1184 (21.6%) samples were positive and all 14 HR-HPV types included in the assay were detected (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). HR-HPV 52, 58 and 16 were the most prevalent with 20.4%, 12.8% and 11.7%, respectively ( Fig 1 ). Download: PNG larger image TIFF original image Fig 1. HR-HPV prevalence. The numbers above the bars indicate the total number of detections by Anyplex PCR, including multiple detections in a single sample (100 samples were positive for more than one genotype). https://doi.org/10.1371/journal.pone.0363215.g001 In-house PCR results and comparison to Anyplex TM II HPV HR detection. Of the 1302 samples tested, 277 (21.3%) were PCR-positive and 1025 (78.7%) were negative. Overall, 41 samples were positive by PCR, but negative using Anyplex, while 37 samples were positive by Anyplex, but negative by PCR (8 different HPV types were concerned, n = 22 were identified as HPV 52). Of the 24 samples classified as invalid after Anyplex testing, 7 were positive and 17 were negative by PCR. The 94 Anyplex borderline samples yielded 10 positive and 84 negative results by in-house PCR. Comparison between cytology and DNA detection results A total of 23 samples from women with abnormal cytology were positive in both PCR and Anyplex, while 4 were positive only by Anyplex and 8 only by PCR. Of the 3 samples from women with cancer, 1 was PCR negative and invalid by Anyplex, while the other two were positive with both methods. Among the 114 women with abnormal cytology, 83 had a negative result by in-house PCR, while Anyplex yielded 71 negative, 5 invalid and 11 borderline results ( Table 3 ). Among the 1151 women with normal cytology, 234 were positive by PCR and 217 by Anyplex ( Table 4 ). Of the 34 samples with invalid cytology, 10 and 8 were tested positive by PCR and by Anyplex, respectively ( Table 3 ). Download: PNG larger image TIFF original image Table 3. Comparison between cytology results, in-house PCR, and Anyplex (n = 1302). https://doi.org/10.1371/journal.pone.0363215.t003 Download: PNG larger image TIFF original image Table 4. Results of bivariate analysis for Cytology, Anyplex, and in-house PCR results. https://doi.org/10.1371/journal.pone.0363215.t004 Cytology and HR-HPV genotype. Overall, 14 different HR-HPV genotypes were found in participants with normal cytology. The three most common types were HPV 52, HPV 58 and HPV 16 (14.8%, 9.2% and 7.4% respectively). Moreover, 37.3% (81/217) of the women with normal cytology were positive for at least two HR-HPV types ( Fig 2 ). Download: PNG larger image TIFF original image Fig 2. HR-HPV types among participants with normal cytology (n = 217). *There were 48 unique combinations, not detailed here. **Three genotypes: 66/16/18, 52/68/3, 16/39/52, 66/51/31, 58/59/18, 66/52/56, 51/16/68, 58/39/68, 66/16/33, 52/18/68, 66/16/68, 58/39/18, 66/58/52, 58/39/18, 35/68/31, 51/16/52, 59/18/68, 58/33/52 and 58/16/52. ***Four genotypes: 58/51/52/18, 58/51/39/52, 51/39/52/68, 51/39/56/68, 66/51/52/31 and 58/16/39/56. ****Five genotypes: 58/51/52/28/68 and 45/58/16/18/31. https://doi.org/10.1371/journal.pone.0363215.g002 HR-HPV genotypes associated with abnormal cytology were HPV 16, 18, 33, 39, 51, 52, 58 and 68. HPV 52 was the most common (n = 6/27, 22.2%), followed by HPV 58 (n = 4/27, 14.8%) and HPV 16 and 33 with 2 samples each. In addition, 22.2% of the women with abnormal cytology were positive for two HR-HPV types, while infections with more types were less common ( Fig 3 ). Download: PNG larger image TIFF original image Fig 3. HR-HPV types among participants with abnormal cytology (n = 27). * Two genotypes: 16/33, 51/39, 33/52, 18/16, 51/16, 16/45. **Four genotypes: 58/39/68/52. ***Five genotypes: 58/59/16/39/52 and 58/45/39/31/52. HR-HPV genotypes 16 and 33, respectively, were detected in the two cancer patients with an Anyplex positive result. https://doi.org/10.1371/journal.pone.0363215.g003 Bivariate analysis for Cytology, Anyplex and in-house PCR results Due to the low number of cancer patients (0.2% of all women with analysable cytology results), we combined that category with the abnormal cytology category for the purpose of bivariate and multivariable analyses (thus, “abnormal cytology” comprises both categories in these sections). After analysis, two variables, namely province and age, were significant ( Table 4 ). Women aged ≥ 40 had a higher probability of having abnormal cytology than younger women (OR: 1.8, 95% CI 1.2–2.7, p = 0.002), as did women living in Luangprabang province compa
## Related Clinical Research

- [Hepatitis C treatment access in Los Angeles County: barriers, facilitators, and linkage-to-cure fi](https://medichelpline.com/clinical-feed/plos-one-9-exploring-barriers-and-facilitators-to-hepatitis-c-virus-treatment-access-in.md)
- [NOX2 drives HBV replication via ROS-induced autophagy in cell models](https://medichelpline.com/clinical-feed/pubmed-43059380.md) (DOI: 10.3892/ijmm.2026.6054)
- [Infections in Adult Liver Transplant Hospitalizations Linked to Higher Mortality and Costs](https://medichelpline.com/clinical-feed/plos-one-2-burden-and-impact-of-infections-among-adult-liver-transplantation-related.md)
- [Targeting the NTCP–EGFR Complex to Block HBV and HDV Entry](https://medichelpline.com/clinical-feed/pubmed-43008022.md) (DOI: 10.1073/pnas.2603986123)
- [Prevalence of protective anti-HBs among women delivering at Kawempe National Referral Hospital, Ug](https://medichelpline.com/clinical-feed/medrxiv-18-prevalence-of-protective-hepatitis-b-surface-antibody-levels-and-associated.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.